Page 3 - Stephan Jackman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in the first quarter of 2024. Also Read: EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder. As a follow-up to our "IND submission" release in August, the FDA has granted us a "Study May Proceed" notifica

Alzamend Neuro, Inc. , a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease , bipolar disorder , major depressive disorder and...

Safety aspects of AL001 development may qualify for pathway for FDA approval Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a...

Topline data from a phase 2a, multiple ascending dose study identified a maximum tolerated dose for development of AL001, an investigational lithium-delivery system, according to a press release from manufacturer Alzamend Neuro.AL001 is a lithium-salicylate-L-proline engineered ionic cocrystal being developed as an oral treatment for patients with neurodegenerative, neurological and

Panel to be held on Tuesday, June 20, 2023 at 2:00 PM ET ... | June 13, 2023